A Phase 3 interventional study of Iloperidone and Placebo in Schizophrenia, sponsored by Vanda Pharmaceuticals. Completed at 63 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-17.
Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.
Among the 11 studies testing iloperidone in Schizophrenia, this one has the largest enrollment, is one of 2 that started in 2011, is one of 4 in phase 3, and was the 3rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:
Vanda Pharmaceuticals · Sites in United States
Ages 18–65
Vanda Pharmaceuticals · Sites in United States
Ages 12–17
By country, each count listing its studies:
iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2011.
This study's enrollment of 635 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 260 across the 11 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 5 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 8 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
1 of the studies testing iloperidone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06961968Phase 3Vanda PharmaceuticalsRandomized Withdrawal Study in Patients With Schizophrenia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing iloperidone in Schizophrenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
Inclusion Criteria:
Exclusion Criteria:-
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After meeting all entry criteria, completing a 1-week open-label iloperidone titation period (up to 12 mg/day), followed by a 14-24 week open-label iloperidone flexible dose-stabilization period (up to 24 mg/day), approximately 260 patients will be randomized to one of two arms in a 1:1 ratio of iloperidone (flexible dosing 8-24 mg/day) to placebo. Post-randomization double-blind study medication will be administered orally twice daily for up to 26 weeks to evaluate relapse prevention. Subsequently, during the extension period, after a 1-week mock double-blind titration, open-label iloperidone (8-24 mg/day) is administered for up to 51 weeks to evaluate long-term safety.
Drug: Iloperidone
Post-randomization matching placebo is administered orally bid during the double-blind period.
Drug: Placebo
Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
Also known as: Fanapt®
Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
Time to Relapse or Impending Relapse
Relapse or impending relapse was defined as any of the following: hospitalization due to worsening of schizophrenia; increase (worsening) of the PANSS total score of greater than or equal to 30% from randomization, PANSS total score confirmed at a second visit conducted within 1-7 days; clinically significant emergent or worsening suicidal, homicidal, or aggressive behavior; a CGI-Improvement (CGI-I) score of 6 (much worse) or 7 (very much worse) after randomization; a dose increase in study medication or a need for additional open-label antipsychotic treatment.
Time frame: Up to 26 weeks post-randomization
PANSS Total Score, Change From Baseline to Last Visit
The 30-item Positive and Negative Syndrome Scale (PANSS) was developed to assess the severity of symptoms of schizophrenia. The PANSS items are divided into positive, negative, and general psychopathology factors. All items were rated on a scale of 1 (absent) to 7 (extremely severe). The PANSS total score (or rating) is the sum of all 30 PANSS items taken together (the sum of its 3 subscales), with a maximum score of 210. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.
Time frame: Up to 26 weeks post-randomization
CGI-S, Last Visit
The 7-item Clinical Global Impression of Severity (CGI-S) scale was developed to assess the overall, absolute degree of illness at any point in time. A rating of 1 is equivalent to "normal, not at all ill," and a rating of 7 is equivalent to "among the most extremely ill patients."
Time frame: Up to 26 weeks post-randomization
SDS Total Score, Change From Baseline to Last Visit
The Sheehan Disability Scale (SDS) a self-reported measure that was developed to assess functional impairment in 3 inter-related domains (i.e., work/school, social, and family life). It is a 10-point visual analog scale with 0 being not impaired at all and 10 extremely impaired. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.
Time frame: Up to 26 weeks post-randomization
| Milestone | Iloperidone | Placebo |
|---|---|---|
| Started | 635 | 0 |
| Completed | 309 | 0 |
| Not completed | 326 | 0 |
| Withdrew: Withdrawal by subject | 107 | 0 |
| Withdrew: Adverse event | 92 | 0 |
| Withdrew: Administrative problems | 30 | 0 |
| Withdrew: Lack of efficacy | 28 | 0 |
| Withdrew: Abnormal laboratory value | 25 | 0 |
| Withdrew: Lost to follow-up | 24 | 0 |
| Withdrew: Protocol violation | 13 | 0 |
| Withdrew: Abnormal test | 6 | 0 |
| Withdrew: Death | 1 | 0 |
| Milestone | Iloperidone | Placebo |
|---|---|---|
| Started | 153 | 150 |
| Completed | 76 | 102 |
| Not completed | 77 | 48 |
| Withdrew: Administrative problems | 45 | 29 |
| Withdrew: Withdrawal by subject | 14 | 10 |
| Withdrew: Lost to follow-up | 6 | 4 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Abnormal laboratory value | 4 | 2 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Abnormal test | 1 | 0 |
| Withdrew: Death | 1 | 0 |
Relapse or impending relapse was defined as any of the following: hospitalization due to worsening of schizophrenia; increase (worsening) of the PANSS total score of greater than or equal to 30% from randomization, PANSS total score confirmed at a second visit conducted within 1-7 days; clinically significant emergent or worsening suicidal, homicidal, or aggressive behavior; a CGI-Improvement (CGI-I) score of 6 (much worse) or 7 (very much worse) after randomization; a dose increase in study medication or a need for additional open-label antipsychotic treatment.
| Days | Iloperidone | Placebo |
|---|---|---|
| Time to Relapse or Impending Relapse | NA (NA to NA) | 99 (57 to 122) |
The 30-item Positive and Negative Syndrome Scale (PANSS) was developed to assess the severity of symptoms of schizophrenia. The PANSS items are divided into positive, negative, and general psychopathology factors. All items were rated on a scale of 1 (absent) to 7 (extremely severe). The PANSS total score (or rating) is the sum of all 30 PANSS items taken together (the sum of its 3 subscales), with a maximum score of 210. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.
| units on a scale | Iloperidone | Placebo |
|---|---|---|
| PANSS Total Score, Change From Baseline to Last Visit | 1.1 ± 1.12 | 12.4 ± 1.15 |
The 7-item Clinical Global Impression of Severity (CGI-S) scale was developed to assess the overall, absolute degree of illness at any point in time. A rating of 1 is equivalent to "normal, not at all ill," and a rating of 7 is equivalent to "among the most extremely ill patients."
| units on a scale | Iloperidone | Placebo |
|---|---|---|
| CGI-S, Last Visit | 3.0 ± 0.89 | 3.6 ± 1.11 |
The Sheehan Disability Scale (SDS) a self-reported measure that was developed to assess functional impairment in 3 inter-related domains (i.e., work/school, social, and family life). It is a 10-point visual analog scale with 0 being not impaired at all and 10 extremely impaired. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.
| units on a scale | Iloperidone | Placebo |
|---|---|---|
| SDS Total Score, Change From Baseline to Last Visit | -0.2 ± 0.54 | 1.8 ± 0.61 |
Collected over Cross-Titration Phase (1 week) and Stabilization Phase (14-24 weeks); Relapse-prevention phase (up to 26 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Iloperidone (Cross-titration and Stabilization Phase) | 1/629 (0.2%) | 21/629 (3.3%) | 244/629 (38.8%) |
| Iloperidone (Relapse-prevention Phase) | 1/151 (0.7%) | 6/151 (4%) | 16/151 (10.6%) |
| Placebo (Relapse-prevention Phase) | 0/150 (0%) | 4/150 (2.7%) | 30/150 (20%) |
| Event | Iloperidone (Cross-titration and Stabilization Phase) | Iloperidone (Relapse-prevention Phase) | Placebo (Relapse-prevention Phase) |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 9/629 | 2/151 | 2/150 |
| Acute psychosisPsychiatric disorders | 0/629 | 0/151 | 1/150 |
| Suicidal ideationPsychiatric disorders | 1/629 | 0/151 | 1/150 |
| ArrhythmiaCardiac disorders | 0/629 | 1/151 | 0/150 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/629 | 1/151 | 0/150 |
| HypernatraemiaMetabolism and nutrition disorders | 0/629 | 1/151 | 0/150 |
| HyponatraemiaMetabolism and nutrition disorders | 0/629 | 1/151 | 0/150 |
| ConvulsionNervous system disorders | 0/629 | 1/151 | 0/150 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/629 | 1/151 | 0/150 |
| Hepatitis acuteHepatobiliary disorders | 1/629 | 0/151 | 0/150 |
| Event | Iloperidone (Cross-titration and Stabilization Phase) | Iloperidone (Relapse-prevention Phase) | Placebo (Relapse-prevention Phase) |
|---|---|---|---|
| DizzinessNervous system disorders | 73/629 | 4/151 | 4/150 |
| SchizophreniaPsychiatric disorders | 8/629 | 1/151 | 13/150 |
| SomnolenceNervous system disorders | 52/629 | 2/151 | 0/150 |
| Dry mouthGastrointestinal disorders | 43/629 | 0/151 | 0/150 |
| HeadacheNervous system disorders | 40/629 | 3/151 | 5/150 |
| InsomniaPsychiatric disorders | 35/629 | 3/151 | 7/150 |
| Weight IncreasedInvestigations | 34/629 | 2/151 | 4/150 |
| NauseaGastrointestinal disorders | 32/629 | 2/151 | 0/150 |
| Age, Continuous(years) | Iloperidone | Placebo | Total |
|---|---|---|---|
| Mean | 38.4 ± 11.3 | 38.2 ± 11.1 | 38.3 ± 11.2 |
| Sex: Female, Male(Participants) | Iloperidone | Placebo | Total |
|---|---|---|---|
| Female | 57 | 68 | 125 |
| Male | 96 | 82 | 178 |
| Race/Ethnicity, Customized(Participants) | Iloperidone | Placebo | Total |
|---|---|---|---|
| Caucasian | 74 | 77 | 151 |
| Black | 31 | 28 | 59 |
| Asian | 38 | 40 | 78 |
| Pacific Islander | 1 | 0 | 1 |
| Other | 9 | 5 | 14 |
Ran from Feb 2011 to primary completion in Mar 2014, 37 months.
Results were first posted in Jul 2023, 9 years 4 months after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 37 months is above that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iloperidone